Immunological disorders cause imbalances in the immune system. In cases of immune deficiency, the body’s ability to fight invaders is decreased, becoming vulnerable to infections or cancers. In cases of autoimmunity, the immune system goes on to attack and damage its own tissues. Autoimmune diseases include a wide range of diseases involve the nervous, gastrointestinal, skin, connective and endocrine tissues. These disorders affect more than 500 million people in the developed world; and the prevalence is steadily increasing. Management and treatment of these diseases represents a substantial economic burden. Despite progress made to date in therapeutic development, there are still many patients left inadequately addressed.
Cytokine dysregulation plays a key role in the development of autoimmune diseases. Anti-cytokine monoclonal antibodies (e.g. anti-TNF alpha, anti-IL-6 and anti-IL-17) have been developed as effective treatments for these diseases. Recent advances in translational medicines have revealed new roles for cytokines in causing several devastating immunological diseases including graft-versus-host disease and macrophage activation syndrome. Selecting targets from clinical observations like these, and utilizing our proprietary human single B cell cloning technology platform, Elixiron is developing originally human anti-cytokine antibodies as innovative therapeutics for autoimmune and inflammatory disease.